BK Virus Infection Clinical Trial
Official title:
Safety and Efficacy of Mycophenolic Acid Withdrawal With Conversion to Zortress (Everolimus) in Renal Transplant Recipients With BK Virus Infection
This study is examining the safety and efficacy of converting anti-rejection therapy from
mycophenolic acid (MPA) to Zortress (everolimus) in renal transplant recipients with BK
virus infection.
The study will also determine if immune monitoring tests can detect an association between
BK virus infection and transplant rejection episodes, based on the specific BKV infection
treatment regimen.
The investigators hypothesize that an anti-rejection regimen with Zortress (everolimus) and
tacrolimus + prednisone will be superior to a standard regimen of reduced dose MPA and
tacrolimus + prednisone in patients who have undergone renal transplantation and have active
BKV infections.
This is a pilot study designed as a single center, randomized, open-label trial study
comparing the safety and efficacy of MPA discontinuation with the addition of Zortress
(everolimus) versus standard immunosuppression reduction in adult patients who have
undergone a renal transplant and who have evidence of BKV infection. All kidney transplant
recipients at UCSF are screened for BKV in the urine and plasma at months 1, 3, 6, 9, and 12
post-transplantation. The presence of viruria > 1 million copies/mL and/or viremia prompts a
50% reduction in the MPA dose as well as monthly monitoring of BKV in the urine and plasma.
Renal transplant patients found to have BK viruria > 1 million copies/mL and/or viremia >
500 copies/mL on any screening lab will be eligible for enrollment.
Before any study-related evaluations are performed, the patient must give written informed
consent. Once consent is obtained, patients will be randomized in consecutive blocks of 10,
such that there will be 5 patients allocated to each group for each block. Only the study
coordinator will have access to the block sequences. Patients will be randomized to one of
two groups: group 1 will undergo MPA discontinuation with the addition of Zortress
(everolimus) to their current regimen of tacrolimus and prednisone; group 2 will undergo a
50% dose reduction in MPA and continue with tacrolimus and prednisone.
The two groups will be as follows: All patients in group 1 will undergo discontinuation of
MPA and will receive Zortress (everolimus) at a starting dose of 0.75 mg PO b.i.d. (1.5
mg/day). Everolimus whole blood trough levels will be monitored at pre-specified time points
to achieve a range of 3-8 ng/mL. Group 1 patients will continue on prednisone and tacrolimus
with a target whole blood trough level of 3-6 ng/mL. Group 2 patients will continue with
tacrolimus (target trough level of 6-10 ng/mL), prednisone, and undergo a 50% reduction of
the MPA dose. At months 1, 2, and 3 post-randomization urine and plasma BKV levels will be
re-checked. Renal allograft biopsies will be done for cause as clinically indicated.
Tacrolimus trough levels are lower in the Zortress (everolimus) arm in order to minimize any
potential nephrotoxicity with this drug combination as well as minimize the risk of
over-immunosuppression.
In all patients, routine transplant monitoring labs will be performed monthly as part of
standard of care including a measurement of BUN and Cr, CBC, tacrolimus trough levels, urine
protein excretion and fasting lipids.
During the 3 month treatment period patients will be seen in clinic at baseline and months
1, 2, and 3 for follow-up. The assessment to address the primary objective will be performed
at the end of the treatment period (Month 3). An interim analysis will be performed once 50%
enrollment is reached.
In a sub-group of patients (30 patients total; 15 in group 1 and 15 in group 2) using our
whole-blood assay measuring p70S6 kinase phosphorylation, the investigators will investigate
the correlation between inhibition of p70S6 kinase phosphorylation with BKV replication.
Finally, by measuring both p70S6 phosphorylation inhibition as well as expression of the
NFAT-regulated genes IL-2, interferon gamma and GM-CSF, the investigators will correlate
rejection episodes in patients maintained on lower immunosuppression alone versus those on a
Zortress (everolimus) -based regimen. As patients are assigned to their intervention group
based on the randomization scheme they will be offered enrollment in this sub-group
analysis. All patients will be sequentially enrolled in the sub-group analysis until the 30
subject goal is reached with 15 subjects per group.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02758288 -
BK Virus Post-Kidney Transplant: New Practice Versus Traditional Approach
|
||
Active, not recruiting |
NCT05026021 -
Prediction of BKvirus Nephropathy Risk by the NEPHROVIR Method in Kidney Transplant Patients With BKvirus Viremia
|
||
Recruiting |
NCT05511779 -
Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation
|
Phase 2 | |
Recruiting |
NCT05183490 -
R-MVST Cells for Treatment of Viral Infections
|
Phase 1 | |
Active, not recruiting |
NCT00684372 -
BK Viremia After Renal Transplantation
|
N/A | |
Recruiting |
NCT06219616 -
Prediction of BK Virus Reactivation in Kidney Transplant Recipient
|
N/A | |
Not yet recruiting |
NCT05264259 -
New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies
|
||
Terminated |
NCT05305040 -
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
|
Phase 2/Phase 3 | |
Completed |
NCT04605484 -
Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia
|
Phase 2 | |
Terminated |
NCT04390113 -
Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)
|
Phase 3 | |
Withdrawn |
NCT02313844 -
Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)
|
Phase 1 | |
Completed |
NCT03532971 -
Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes
|
||
Recruiting |
NCT02479698 -
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
|
Phase 2 | |
Recruiting |
NCT05101213 -
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
|
Phase 1 | |
Completed |
NCT01789203 -
Ciprofloxacin for Prevention of BK Infection
|
Phase 4 | |
Completed |
NCT04693637 -
Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
|
Phase 2/Phase 3 | |
Recruiting |
NCT05618275 -
Role of Neutralizing Antibodies in the Prediction and Treatment of BK Virus Infection in Hematopoietic Stem Cell Allograft Patients at the Pediatric Oncology-hematology Department of the HUS
|
||
Recruiting |
NCT04542733 -
The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus in Treatment of BK Virus Infection in Kidney Transplantation Recipient
|
N/A | |
Recruiting |
NCT05042076 -
BK With VST for Kidney Transplant Patients
|
Phase 1 | |
Completed |
NCT04294472 -
A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients
|
Phase 2 |